THIO has a ‘Telomerase-Mediated’ and Telomere-Targeted Mode of Action.
Telomerase is present in 90% of human cancer cells and contributes significantly to proliferative abilities and immortality of cancer cells. It is either absent or shows low activity in normal cells. THIO(6-thio-dG) is recognized by telomerase and incorporated into telomeres. Once incorporated, it compromises telomere structure and function, leading to ‘uncapping’ of the chromosome ends resulting in rapid tumor cell death.
Mender et al. A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells. Oncoscience. 2015 Aug 22;2(8):693-5. https://www.ncbi.nlm.nih.gov/pubmed/26425659
Mender, et al. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-
Mender et al. Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 2018 Aug;20(8):826-837. https://www.ncbi.nlm.nih.gov/pubmed/30015158
Reyes-Uribe et al. Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene. 2018 Jul;37(30):4058-4072. https://www.ncbi.nlm.nih.gov/pubmed/29695835
Sengupta et al. Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors. Mol Cancer Ther. 2018 Jul;17(7):1504-1514. https://www.ncbi.nlm.nih.gov/pubmed/29654065
Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019 May;20(5):299-309. https://www.ncbi.nlm.nih.gov/pubmed/30760854
Zhang et al. Induction of Telomere Dysfunction
Zhang G, Shay JW. Inducing rapid telomere irreparable damage in telomerase-expressing cancers. Oncotarget. 2018 Nov 9;9(88):35803-35804. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254679/